Research ArticleArticle
Correction of the ΔPhe508 Cystic Fibrosis Transmembrane Conductance Regulator Trafficking Defect by the Bioavailable Compound Glafenine
Renaud Robert, Graeme W. Carlile, Jie Liao, Haouaria Balghi, Pierre Lesimple, Na Liu, Bart Kus, Daniela Rotin, Martina Wilke, Hugo R. de Jonge, Bob J. Scholte, David Y. Thomas and John W. Hanrahan
Molecular Pharmacology June 2010, 77 (6) 922-930; DOI: https://doi.org/10.1124/mol.109.062679
Renaud Robert
Graeme W. Carlile
Jie Liao
Haouaria Balghi
Pierre Lesimple
Na Liu
Bart Kus
Daniela Rotin
Martina Wilke
Hugo R. de Jonge
Bob J. Scholte
David Y. Thomas
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleArticle
Correction of the ΔPhe508 Cystic Fibrosis Transmembrane Conductance Regulator Trafficking Defect by the Bioavailable Compound Glafenine
Renaud Robert, Graeme W. Carlile, Jie Liao, Haouaria Balghi, Pierre Lesimple, Na Liu, Bart Kus, Daniela Rotin, Martina Wilke, Hugo R. de Jonge, Bob J. Scholte, David Y. Thomas and John W. Hanrahan
Molecular Pharmacology June 1, 2010, 77 (6) 922-930; DOI: https://doi.org/10.1124/mol.109.062679
Research ArticleArticle
Correction of the ΔPhe508 Cystic Fibrosis Transmembrane Conductance Regulator Trafficking Defect by the Bioavailable Compound Glafenine
Renaud Robert, Graeme W. Carlile, Jie Liao, Haouaria Balghi, Pierre Lesimple, Na Liu, Bart Kus, Daniela Rotin, Martina Wilke, Hugo R. de Jonge, Bob J. Scholte, David Y. Thomas and John W. Hanrahan
Molecular Pharmacology June 1, 2010, 77 (6) 922-930; DOI: https://doi.org/10.1124/mol.109.062679
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement